Patents by Inventor Arthur M. Krieg

Arthur M. Krieg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190062743
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties.
    Type: Application
    Filed: August 30, 2018
    Publication date: February 28, 2019
    Applicant: Translate Bio MA, Inc.
    Inventors: Eugen Uhlmann, Markus Weber, Romesh R. Subramanian, Thomas Dino Rockel, Arthur M. Krieg
  • Publication number: 20190046638
    Abstract: Provided are methods and compositions for modulating an immune response or for treating a disease or condition in a subject, such as cancer, infection, autoimmune disease, allergy, and asthma. The methods involve systemically administering to a subject a particle comprising a surface and an interior, wherein the surface of the particle comprises an antigen, the interior of the particle comprises an immune modulating agent, and the subject is or has been primed to mount an antibody response to the antigen. The antibody response to the particle permits Fc receptor-bearing target cells to take up the particle, thereby delivering the immune modulating agent to the target cells and modulating an immune response of the subject. In various embodiments, the immune modulating agent can be selected from the group consisting of therapeutic agents, immune activators, and immune suppressors. In certain embodiments, the immune activator is a TLR agonist, e.g, a CpG oligodeoxynucleotide.
    Type: Application
    Filed: March 31, 2017
    Publication date: February 14, 2019
    Inventor: Arthur M. KRIEG
  • Patent number: 10174323
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Methods for modulating expression of ATP2A2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of ATP2A2.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: January 8, 2019
    Assignees: The General Hospital Corporation, Translate Bio MA, Inc.
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 10174328
    Abstract: Methods for modulating expression of SMN1 and/or SMN2 in cells obtained from subjects having ALS or in subjects having ALS using single stranded oligonucleotides are provided. Methods for treating ALS using single stranded oligonucleotides are also provided.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: January 8, 2019
    Assignee: Translate Bio MA, Inc.
    Inventors: Arthur M. Krieg, James Barsoum
  • Patent number: 10174315
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: January 8, 2019
    Assignees: The General Hospital Corporation, Translate Bio MA, Inc.
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Publication number: 20180298384
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2 that comprises exon 7. Methods for modulating expression of SMN1 or SMN2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of SMN1 or SMN2.
    Type: Application
    Filed: January 16, 2018
    Publication date: October 18, 2018
    Applicants: Translate Bio MA, Inc., The General Hospital Corporation
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 10093924
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: October 9, 2018
    Assignee: Translate Bio MA, Inc.
    Inventors: Eugen Uhlmann, Markus Weber, Romesh Subramanian, Thomas Dino Rockel, Arthur M. Krieg
  • Patent number: 10059941
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2 that comprises exon 7. Methods for modulating expression of SMN1 or SMN2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of SMN1 or SMN2.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: August 28, 2018
    Assignees: Translate Bio MA, Inc., The General Hospital Corporation
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 10058623
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of UTRN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of UTRN. Methods for modulating expression of UTRN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of UTRN.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: August 28, 2018
    Assignees: Translate Bio MA, Inc., The General Hospital Corporation
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Publication number: 20180223282
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 9, 2018
    Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Publication number: 20180171338
    Abstract: The present invention relates generally to immunostimulatory nucleic acids, compositions thereof and methods of using the immunostimulatory nucleic acids. In particular the invention relates to palindrome-containing immunostimulatory nucleic acids and the use of these nucleic acids in treating disease.
    Type: Application
    Filed: February 5, 2018
    Publication date: June 21, 2018
    Applicant: Adiu Tide Pharmaceuticals GmbH
    Inventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg, Ulrike Samulowitz, Bernard O. Noll
  • Publication number: 20180030444
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided.
    Type: Application
    Filed: September 8, 2017
    Publication date: February 1, 2018
    Applicant: Translate Bio MA, Inc.
    Inventors: Eugen Uhlmann, Romesh Subramanian, Arthur M. Krieg
  • Publication number: 20180000851
    Abstract: Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-?) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.
    Type: Application
    Filed: December 22, 2015
    Publication date: January 4, 2018
    Inventor: Arthur M. KRIEG
  • Patent number: 9790494
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: October 17, 2017
    Assignee: Translate Bio MA, Inc.
    Inventors: Eugen Uhlmann, Romesh Subramanian, Arthur M. Krieg
  • Patent number: 9732341
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: August 15, 2017
    Assignee: Translate Bio MA, Inc.
    Inventors: Eugen Uhlmann, Markus Weber, Romesh Subramanian, Thomas Dino Rockel, Arthur M. Krieg
  • Patent number: 9732340
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: August 15, 2017
    Assignee: Translate Bio MA, Inc.
    Inventors: Eugen Uhlmann, Markus Weber, Romesh Subramanian, Thomas Dino Rockel, Arthur M. Krieg
  • Publication number: 20170211065
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties.
    Type: Application
    Filed: January 26, 2017
    Publication date: July 27, 2017
    Applicant: RaNA Therapeutics, Inc.
    Inventors: Eugen Uhlmann, Markus Weber, Romesh Subramanian, Thomas Dino Rockel, Arthur M. Krieg
  • Patent number: 9580708
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties. Methods of making and uses of the described compounds are also provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 28, 2017
    Assignee: RaNA Therapeutics, Inc.
    Inventors: Eugen Uhlmann, Markus Weber, Romesh Subramanian, Thomas Dino Rockel, Arthur M. Krieg
  • Publication number: 20160222391
    Abstract: Methods for modulating expression of SMN1 and/or SMN2 in cells obtained from subjects having ALS or in subjects having ALS using single stranded oligonucleotides are provided. Methods for treating ALS using single stranded oligonucleotides are also provided.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 4, 2016
    Applicant: RaNA Therapeutics, Inc.
    Inventors: Arthur M. Krieg, James Barsoum
  • Publication number: 20150315585
    Abstract: The disclosure provides multimeric oligonucleotide compounds, comprising two or more target-specific oligonucleotides (e.g., antisense oligonucleotides (ASOs)), each being resistant to cleavage, and linked together by a cleavable linker. In particular, two or more linked target-specific oligonucleotides, each to a different target, allows concomitant inhibition of multiple genes' expression levels, while exhibiting favorable pharmacokinetic and pharmacodynamic properties.
    Type: Application
    Filed: April 28, 2015
    Publication date: November 5, 2015
    Applicant: RaNA Therapeutics, Inc.
    Inventors: Eugen Uhlmann, Romesh Subramanian, Arthur M. Krieg